2.A Case of Deep Vein Thrombosis and Pulmonary Thromboembolism after Intravenous Immunoglobulin Therapy.
Yu Ji LEE ; Jae Uk SHIN ; Jeeyun LEE ; Kihyun KIM ; Won Seog KIM ; Jin Seok AHN ; Chul Won JUNG ; Won Ki KANG
Journal of Korean Medical Science 2007;22(4):758-761
Although high-dose intravenous immunoglobulin (IVIG) is generally considered a safe medication for various immune-mediated diseases, thrombotic events have been reported as a complication of the therapy. We report a case who developed thrombotic complications after receiving IVIG. A 56-yr-old woman with idiopathic thrombocytopenic purpura received IVIG at a dose of 400 mg/kg/day for five days. Three days after the administration of IVIG, the patient developed painful edema in the left leg. Lower extremity doppler ultrasound revealed deep vein thrombosis in the left leg. Chest computed tomography (CT) scan demonstrated a filling defect indicating thromboembolism of the right pulmonary artery. After three weeks of enoxaparin therapy, her symptoms and pulmonary embolism on CT improved. This case suggests clinicians should be cautious in the development of thromboembolism by administration of IVIG, especially in patients with thrombophilia.
Female
;
Humans
;
Immunoglobulins, Intravenous/*adverse effects/therapeutic use
;
Middle Aged
;
Pulmonary Embolism/*chemically induced
;
Purpura, Thrombocytopenic, Idiopathic/drug therapy
;
Venous Thrombosis/*chemically induced
4.Use of intravenous tranexamic acid in total knee arthroplasty: a meta-analysis of randomized controlled trials.
De-Jie FU ; Cheng CHEN ; Lin GUO ; Liu YANG
Chinese Journal of Traumatology 2013;16(2):67-76
OBJECTIVEThe effect of tranexamic acid (TA) on patients receiving total knee arthroplasty (TKA) has been reported in many small clinical trials. But single trials are not sufficient enough to clarify the effectiveness and safety of TA. So, we carried out a meta-analysis of randomized controlled trials to investigate the efficacy and safety of the intravenous use of TA in TKA.
METHODSLiteratures were retrieved in Cochrane Library, OVID, PubMed, EMBASE, CNKI and Wanfang Data. All the related literatures were checked by two independent investigators and only the high quality randomized controlled trials were enrolled. Relevant data were analyzed using RevMan 5.1 to compare the difference of blood loss, transfusion and complications between TA group and control group.
RESULTSThere were 353 related literatures and only 22 randomized controlled trials met the inclusion criteria. The use of TA in TKA significantly reduced total blood loss by a mean of 435.41 ml (95% CI 300.62-570.21, P less than 0.01), post-operative blood loss by a mean of 406.69 ml (95% CI 333.16-480.22, P less than 0.01). TA also significantly lowered the transfusion rate (risk difference 0.30, 95% CI 0.21-0.39, P less than 0.01) and transfusion volume (mean difference 0.95 unit, 95% CI 0.53-1.37, P less than 0.01). The risks between TA group and control group in developing deep vein thrombosis and pulmonary embolism were not statistically significant.
CONCLUSIONTA is beneficial for patients undergoing TKA, which can significantly reduce total blood loss, postoperative blood loss, transfusion rate, and transfusion volume. Meanwhile TA is recommended to reduce deep vein thrombosis and pulmonary embolism following TKA.
Antifibrinolytic Agents ; therapeutic use ; Arthroplasty, Replacement, Knee ; Blood Loss, Surgical ; prevention & control ; Blood Transfusion ; Humans ; Postoperative Hemorrhage ; prevention & control ; Pulmonary Embolism ; chemically induced ; Randomized Controlled Trials as Topic ; Tranexamic Acid ; adverse effects ; therapeutic use ; Venous Thrombosis ; chemically induced
5.Clinicopathologic Review of Pulmonary Silicone Embolism with Special Emphasis on the Resultant Histologic Diversity in the Lung: A Review of Five Cases.
Kyung Young CHUNG ; Se Hoon KIM ; Il Hoon KWON ; Young Sik CHOI ; Tae Woong NOH ; Tae Jung KWON ; Dong Hwan SHIN
Yonsei Medical Journal 2002;43(2):152-159
It is known that the subcutaneous injection of silicone can lead to severe pulmonary complications, followed in some patients by respiratory failure. Currently, silicone is being increasingly applied in the field of plastic surgery and, unfortunately, the illicit injection of silicone fluid by uncertified practitioners is not uncommon in Korea. We offer a critical pathologic review of 5 cases of pulmonary silicone embolism following illegal injection to the vaginal wall, four of which were fatal and came to legal autopsy. Our findings again confirm that subcutaneously injected silicone can gain access to the pulmonary vascular tree and cause pulmonary embolism. The histologic changes observed in the lung are variable and include four patterns i.e., the mere presence of silicone emboli, congestion and hemorrhage, acute pneumonitis, and diffuse alveolar damage despite the severe critical course in all cases. We were unable to find any histologic pattern that correlates well with the clinical course. Apart from producing emboli in the pulmonary vessels, subcutaneous injection of silicone can obviously cause serious pulmonary disease due to its ability to induce acute to induce acute pneumonitis and even possibly acute respiratory distress syndrome.
Adult
;
Case Report
;
Fatal Outcome
;
Female
;
Human
;
Injections
;
Middle Age
;
Pulmonary Embolism/*chemically induced/*pathology
;
Silicones/administration & dosage/*adverse effects
;
Vagina
7.Inhibition of ADP-induced platelet aggregation and involvement of non-cellular blood chemical mediators are responsible for the antithrombotic potential of the fruits of Lagenaria siceraria.
Mithun Singh RAJPUT ; Neelam BALEKAR ; Dinesh Kumar JAIN
Chinese Journal of Natural Medicines (English Ed.) 2014;12(8):599-606
AIM:
The fruits of Lagenaria siceraria (Molina) Standl. (Cucurbitaceae), a commonly used vegetable, are reported to possess various medicinal properties. In previous studies, the fibrinolytic potential of an ethanolic extract of fruits of Lagenaria siceraria was investigated in comparison with kaempferol isolated from it. The aim of the present study was to explore its mechanistic antithrombotic potential and antiplatelet activity using a wide dose range in different in vitro and in vivo models, and to quantify the total phenolic, flavonoid, and kaempferol contents using a colorimetric method.
METHOD:
The antithrombotic potential was investigated using tail bleeding time in mice, a plasma recalcification assay, and pulmonary thromboembolism in mice. The antiplatelet activity was studied using an in vitro model to investigate IC50 value.
RESULTS:
A significant amount of total phenols, flavonoids, and kaempferol was quantified in L. siceraria ethanolic extract. An ethanolic extract of the fruits of L. siceraria showed a significant increase in tail bleeding time and plasma recalcification time, significant protection against ADP induced pulmonary thromboembolism in mice, and also inhibited the platelet aggregation induced by ADP in vitro. The study suggested that the fruits of L. siceraria exhibit significant antithrombotic potential due to inhibition of ADP-mediated platelet aggregation and the involvement of various non-cellular chemical mediators of blood.
CONCLUSION
This finding may be helpful in treating the serious consequences of the thrombus formed in blood vessels which include atherothrombotic diseases, such as myocardial or cerebral infarction. So, further investigation should be done for revealing exact mechanism of action behind these types of activities.
Adenosine Diphosphate
;
Animals
;
Calcium
;
blood
;
Cucurbitaceae
;
chemistry
;
Female
;
Fibrinolytic Agents
;
analysis
;
pharmacology
;
therapeutic use
;
Fruit
;
Goats
;
Kaempferols
;
analysis
;
pharmacology
;
therapeutic use
;
Male
;
Mice
;
Phytotherapy
;
Plant Extracts
;
chemistry
;
pharmacology
;
therapeutic use
;
Platelet Aggregation
;
drug effects
;
Platelet Aggregation Inhibitors
;
analysis
;
pharmacology
;
therapeutic use
;
Polyphenols
;
analysis
;
pharmacology
;
therapeutic use
;
Pulmonary Embolism
;
blood
;
chemically induced
;
drug therapy
;
Rats, Wistar
;
Thrombosis
;
prevention & control